Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total revenue	$ 83,177	$ 886,532
Operating costs and expenses
Research and development	9,301,958	6,149,586
Research and Development - Milestone expense for Patagonia Pharmaceuticals LLC	4,000,000
Selling, general and administrative	6,016,615	5,387,164
Total operating expenses	19,318,573	11,536,750
Loss from operations	(19,235,396)	(10,650,218)
Other income (expense)
Interest expense	(228,456)	(15,551)
Interest income	2,445
Other income	75,000
Forgiveness of PPP loan	37,772
(Loss) gain on foreign currency exchange	(23,215)	(3,619)
Total other income (expense)	(136,454)	(19,170)
Loss before provision for income taxes	(19,371,850)	(10,669,388)
Provision (benefit) for income taxes	7,600	(30,242)
Net loss	(19,379,450)	(10,639,146)
Comprehensive Loss	(19,379,450)	(10,639,146)
Dividends on Series A preferred stock		(129,992)
Net loss attributable to common stockholders	$ (19,379,450)	$ (10,769,138)
Basic net loss per share attributable to common stockholders	$ (9.19)	$ (13.31)
Diluted net loss per share attributable to common stockholders	$ (9.19)	$ (13.31)
Basic weighted average number of shares outstanding	2,108,128	808,811
Diluted weighted average number of shares outstanding	2,108,128	808,811
Grant revenue
Total revenue	$ 83,177	$ 590,794
Milestone revenue
Total revenue		$ 295,738